S
acubitril/valsartan is one of a new line of therapeutic agents for patients with heart failure. Given the relationships between kidney disease and structural heart disease, testing the impact of this new agent in patients with chronic kidney disease (CKD) is important. In this issue of Circulation, Haynes and colleagues 1 publish an article that assessed the effects of sacubitril/valsartan on kidney function in patients with CKD and albuminuria.
Sacubitril is an inhibitor of neprilysin (neutral endopeptidase), an enzyme that degrades natriuretic peptides and other vasoactive peptides, including angiotensin II and bradykinin, leading to a variety of actions, including natriuresis, diuresis, vasodilatation, and counterregulation of the renal angiotensin system. 2 However, because it activates the angiotensin system (by raising angiotensin II levels), it is used in combination with angiotensin receptor blockers.
The efficacy of sacubitril/valsartan in heart failure was established in the PARADIGM-HF trial (Prospective Comparison of ARNI With ACE Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure), a large randomized controlled trial of 8442 patients with class II or greater heart failure (ejection fraction <40%) who showed a reduction in death from cardiovascular causes or hospitalization for heart failure from 26.5% to 21.8%, when compared with treatment with angiotensinconverting-enzyme inhibition over a median follow-up of 27 months. 3 Based on the results of this practice changing trial, in 2017, the Canadian Cardiovascular Society Heart Failure guidelines, 4 American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and Heart Failure Society of America updated their guidelines. The US guidelines now include sacubitril/valsartan as firstline therapy in conjunction with guideline-directed medical therapy 5 in patients with heart failure with reduced ejection fraction. The Canadian Cardiovascular Society Heart Failure and US guidelines recommend replacing an angiotensin-convertingenzyme inhibitors or angiotensin II receptor blockers with sacubitril/valsartan in patients with heart failure and reduced ejection fraction who remain symptomatic on angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers.
It is important to note that patients with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m 2 were excluded from the PARADIGM-HF trial. Hence, the tolerability and efficacy of this medication in patients with more advanced CKD (eGFR <30 mL/min/1.73 m 2 ) remains uncertain, although sacubitril/valsartan was noted to be effective in those with eGFR 30 to 60 mL/min/1.73 m 2 (35% of patients within PARADIGM-HF). Indeed, cardiovascular disease and CKD frequently coexist, and cardiovascular events are more common than progression to end-stage kidney disease in patients with CKD. 6 Evidence of structural heart disease is present in the majority of patients with CKD by the time they reach end-stage kidney disease, and acute care visits for heart failure among people with CKD are more than twice as common as for patients without CKD. 6, 7 It is interesting to note that for patients with CKD, a slowing of the rate of decline in eGFR (−1.3 versus −1.8 mL/min/1.73 m 2 per year; P<0.0001) was observed in analyses of secondary outcomes in the PAR-ADIGM-HF trial, especially in the subgroup of patients with diabetes mellitus, 8 even after controlling for differences in blood pressure during treatment. This finding is particularly important because trials investigating the impact on new medications to reduce CKD progression, as well as interventions to improve cardiovascular outcomes, have been prioritized by patients 9 with CKD. Considering all of this information, the study by Haynes and colleagues 1 is timely. Although it is a small randomized trial by cardiology standards, it was powered to detect a difference in measured GFR of 3 mL/ min/1.73m 2 and was conducted in 414 patients with CKD at relatively high risk of CKD progression, including those with an eGFR ≥45 and <60 mL/min/1.73 m 2 and a urine albumin:creatinine ratio >20 mg/mmol or an eGFR of ≥20 and <45 mL/min/1.73 m 2 (regardless of urine albumin:creatinine ratio). Patients were followed for 1 year and received either sacubitril/valsartan 97/103 mg twice daily or irbesartan 300 mg once daily. The goal of the trial was to test the impact of sacubitril/valsartan on surrogate outcomes, including change in measured GFR (the primary outcome) before randomization and again at 12 months. A number of secondary surrogate outcomes were measured, including blood pressure, cardiac markers (N-terminal pro-Btype natriuretic peptide and troponin I), estimated GFR, albuminuria, and serious adverse events. The study was not powered to examine the effect of treatment on cardiovascular mortality and events. Twenty percent of participants lacked GFR measurements at the end of the trial, with multiple imputation and complete case analyses both used to address the issue of missing data.
Mean measured GFR among those enrolled was 34.0 and 34.7 mL/min/1.73 m 2 at baseline in the sacubitril/ valsartan and valsartan groups, respectively, and 65% of patients in both groups had A3 albuminuria (urine albumin:creatinine ratio >30 mg/mmol). Among patients randomized to sacubitril/valsartan versus valsartan, there was no difference in the primary outcome of measured mean GFR at 12 months (29.8 and 29.9 mL/ min/1.73 m, 2 respectively; difference -0.1 mL/min/1.73 m 2 ; P=0.86). Among the secondary outcomes, there was no difference in albuminuria; however, blood pressure, N-terminal pro-B-type natriuretic peptide, and troponin I concentrations were lower with sacubitril/ valsartan treatment. There are important considerations about GFR measurement that are relevant when interpreting the primary outcome. First, an early decline in eGFR (from randomization to 1 month) was apparent, followed by relative stability from 3 to 12 months in both groups. This finding is in keeping with the initial hemodynamic effects expected with the introduction of angiotensin blockade. 10 This finding further suggests that much of the GFR change measured in the study reflects the hemodynamic impact of angiotensin inhibition (apparent in both groups). The study was neither designed nor was it likely sufficiently powered to detect smaller, long-term changes in GFR occurring beyond the first month. There are several additional mechanistic reasons to believe sacubitril may have other glomerular hemodynamic effects that might affect GFR (eg, expected accompanying natriuresis and blood pressure lowering) that could mask any favorable long-term effects on CKD progression that result from progressive parenchymal kidney damage. Longer follow-up or measurement of GFR after withdrawal of these therapies would be required to clarify these issues. Another important limitation is that half of participants in the trial had causes of CKD (eg, hereditary nephritis, tubulointerstitial nephritis), where the pathogenesis of disease progression is not predominantly mediated by glomerulosclerosis, and so disease progression may not be modifiable by this therapy in all patients with CKD who were studied.
What then are the main messages from this trial for patients with CKD and their care providers? Taken alongside the findings of the PARADIGM-HF trial, this study suggests that, when compared with current standard therapy with angiotensin blockers, sacubitril/valsartan is comparably well tolerated in patients with CKD, which provides reassurance about its use in patients with advanced CKD, who also have reduced ejection fraction. Many heart failure therapies are more challenging to use in patients with advanced CKD (Landmark trials of guideline-directed medical therapy for heart failure and their application in patients with CKD is provided in the Table) . Thus, a therapy for patients with CKD and reduced ejection fraction that is not associated with worsening kidney function or hyperkalemia and also promotes blood pressure lowering and natriuresis is attractive for use in patients with CKD.
However, for the majority of patients with CKD who do not have reduced ejection fraction and yet remain at high cardiovascular risk, a larger clinical trial designed to examine the effect of sacubitril/valsartan on clinical end points of cardiovascular mortality and events will be required to determine whether this therapy is effective for reducing cardiovascular risk and improving patient outcomes in the broader CKD population. When one considers that the price of sacubitril/valsartan is >15-fold higher than generic valsartan, understanding whether this new therapy is effective and offers value for money (ie, that higher medication costs are offset by reductions in the cost of hospitalizations for heart disease) in the current setting of constrained healthcare resources seems particularly important.
Finally, does this trial rule out an important impact of sacubitril/valsartan on progression of CKD? It is likely that 
